Cardiovascular events in chronic kidney disease (CKD)—an importance of vascular calcification and microcirculatory impairment

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.

Ohtake T, Kobayashi S, Moriya H, Negishi K, Okamoto K, Maesato K, Saito S. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy. Anangiographic examination. J Am Soc Nephrol. 2005;16:1141–8.

Ikeda T, Gomi T, Kobayashi S, Tsuchiya H. Role of hypertension in asymptomatic cerebral lacunae in the elderly. Hypertension. 1994;23 Suppl 1:1259–62.

Kobayashi S, Ikeda T, Moriya H, Ohtake T, Kumagai H. Asymptomatic cerebral lacunae in patients with chronic kidney disease. Am J Kidney Dis. 2004;44:35–41.

Sarnak MJ, Levy AS, Schoolwerth AC, Coressh J, Culleton B, Hamm LL, MaCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfey M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the AHA councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology, and prevention. Circulation. 2003;108:2154–69.

Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–9.

Steg PG, Bhatt DL, Wilson PWF, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197–206.

Ramos LF, Shintani A, Ikizler TA, Himmelfarb J. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol. 2008;19:593–9.

Cottone S, Lorito MC, Riccobene R, Nardi E, Mule G, Buscemi S, Geraci C, Guarneri M, Arena R, Cerasola G. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. J Nephrol. 2008;21:175–9.

Kim JA. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113(15):1888–904.

Kobayashi S, Oka M, Maesato K, Ikee R, Mano T, Moriya H, Ohtake T. Coronary artery calcification, ADMA, and insulin resistance in CKD patients. CJASN. 2008;3:1289–95.

Kenney KR. Rheology: overlooked component of vascular disease. Clin Appl Thromb Hemost. 2003;9:93–9.

Kobayashi S, Okamoto K, Maesato K, Moriya H, Ohtake T. Important role of blood rheology in atherosclerosis of patients with hemodialysis. Hemodial Int. 2005;9:268–74.

Kobayashi S, Miyamoto M, Kurumatani H, Oka M, Maesato K, Mano T, Ikee R, Moriya H, Ohtake T. Increased leukocyte aggregates are associated with atherosclerosis in patients with hemodialysis. Hemodial Int. 2009;13:286–92.

Aulivola B, Hile CN, Hamdan AD. Major lower extremity in patients with end-stage renal disease. Arch Surg. 2004;139:395–9.

Howard J, O’Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R. Insulin sensitivity and atherosclerosis. Circulation. 1996;93:1809–17.

Moorhead JF, Chan MK, Varghese Z. The role of abnormalities of lipid metabolism in the progression of renal disease. In: Brenner BM, Stein JH, editors. The progressive nature of renal disease. New York: Churchill Livingston; 1986. p. 133–49.

Ikeda T, Gomi T, Hirawa N, Sakurai J, Yoshikawa N. Improvement of insulin sensitivity contributes to blood pressure reduction after weight loss in hypertensive subjects with obesity. Hypertension. 1996;27:1180–6.

Mak RHK, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron. 1992;61:377–82.

Kobayashi S, Maejima S, Ikeda T, Nagase M. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of hemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2000;15:65–70.

Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol. 2002;13(7):1894–900.

Bernardo AP, Oliveira JC, Santos O, Carvalho MJ, Cabrita A, Rodrigues A. Insulin resistance in nondiabetic peritoneal dialysis patients: associations with body composition, peritoneal transport, and peritoneal glucose absorption. Clin J Am Soc Nephrol. 2015;10(12):2205–12.

Dzurik R, Spustova V, Janekova K. The prevalence of insulin resistance in kidney disease patients before the development of renal failure. Nephron. 1995;69:281–5.

Vareesangthip K, Tong P, Wilkinson R, Thomas TH. Insulin resistance and adult polycystic kidney disease. Kidney Int. 1997;52:503–8.

Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, Ritz E. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998;53:1343–7.

Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, Whelton PK, He J. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol. 2003;14:469–77.

DeFronzo RA, Andres R, Edgar P, Walker WG. Carbohydrate metabolism in uremia. Medicine. 1973;52:285–98.

DeFronzo RA, Alvestrand A, Smith D, Hendlerm R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest. 1981;65:563–8.

DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214–23.

Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney diseases. Am J Kidney Dis. 2005;45:275–80.

Sniderman AD, Furberg CD, Keech A, van Lennep JE R, Frohlich J, Jungner I, Walldius G. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 2003;361:777–80.

de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbo supplementation slows progression CKD and improves nutrional status. J Am Soc Nephrol. 2009;20:2075–84.

Hosoya K, Minakuchi H, Wakino S, Fujimura K, Hasegawa K, Komatsu M, Yoshifuji A, Futatsugi K, Shinozuka K, Washida N, Kanda T, Tokuyama H, Hayashi K, Itoh H. Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans. Kidney Int. 2015;87(4):749–60.

Goodman GW, Goldin J, Kuizon DB, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–83.

Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol. 2002;39:695–701.

Tamashiro M, Iseki K, Sunagawa O, Inoue T, Higa S, Afuso H, Fukiyama K. Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis. 2001;38:64–9.

Bursztyn M, Motro M, Grossman E, Shemesh J. Accelerated coronary artery calcification in mildly reduced renal function of high-risk hypertensives: a 3-year prospective observation. J Hypertens. 2003;21:1953–9.

Russo D, Palmiero G, Blasio APD, Balletta MM, Andreucci VE. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis. 2004;44:1024–30.

Fox CS, Larson MG, Keyes MG, Levy D, Clouse ME, Culleton B, O’Donnell CJ. Kidney function is inversely associated with coronary artery calcification in men and women free of cardiovascular disease: the Framingham study. Kidney Int. 2004;66:2017–21.

Mehrotra R, Budoff M, Hokanson JE, Ipp E, Takasu J, Adler S. Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney Int. 2005;68:1258–66.

Arad Y, Newtein D, Cadet F, Roth M, Guerci AD. Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron-beam computed tomographic study. Arterioscler Thromb Vasc Biol. 2001;21:2051–8.

Stuhlinger MC, Abbasi MC, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;287:1420–6.

Boger RH, Bode-Borger SM, Szuba A, Philip ST, Chan JR, Oranee T, Terrence FB, Cooke JP. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation. 1998;98:1842–7.

Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethyl aminohydrolase. Circulation. 1999;99:3092–5.

Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000;20:2032–7.

Kleinstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM, Frolich JC. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999;10:594–600.

Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, Matz W. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen risk and cardiovascular health study). Clin Chem. 2007;53:273–83.

Valkonen VP, Palva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358:2127–8.

Blaha MJ1, DeFilippis AP, Rivera JJ, Budoff MJ, Blankstein R, Agatston A, Szklo M, Lakoski SG, Bertoni AG, Kronmal RA, Blumenthal RS, Nasir K. The relationship between insulin resistance and incidence and progression of coronary artery calcification: the multi-ethnic study of atherosclerosis (MESA). Diabetes Care. 2011;34(3):749–51.

Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003;108:2054–9.

Gawaz MP, Mujais SK, Schmidt B, et al. Platelet-leukocyte aggregates during hemodialysis: effect of membrane type. Artif Organs. 1999;23:29–36.

Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation. 2002;105(18):2166–71.

Jaar BG, Astor BC, Berns JS, Powe NR. Predictors of amputation and survival following lower extremity revascularization in hemodialysis patients. Kidney Int. 2004;65:613–20.

Sumner R. Noninvasive assessment of peripheral arterial occlusive disease. In: Rutherford RB, editor. Vascular disease. 3rd ed. Philadelphia: WB Saunders; 1989. p. 61–111.

Prineas RJ, Harland WR, Janzon L, Kannel W. Recommendations for use of non-invasive methods to detect atherosclerotic peripheral arterial disease in population studies. American Heart Association Council on Epidemiology. Circulation. 1982;65:1561A–6.

Carter SA. Role of pressure measurements in vascular disease. In: Berstein EF, editor. Vascular diagnosis. 4th ed. St Louis: CV Mosby; 1993. p. 486–512.

Yao ST, Hobbs JT, Irvine WT. Ankle systolic pressure measurements in arterial disease affecting the lower extremities. Br J Surg. 1969;56:676–9.

Carter SA, Lezack JD. Digital systolic pressures in the lower limb in arterial disease. Circulation. 1971;43:905–14.

Carter SA. Clinical measurement of systolic pressures in limbs with arterial occlusive disease. JAMA. 1969;207:1869–74.

Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26:517–38.

European Working Group on Chronic Critical Leg Ischemia. Second European consensus document on chronic critical leg ischemia. Circulation. 1991;84:IV1–26.

Larsson JAJ, Castenfors J, Agardh CD, Stenstrom A. Distal blood pressure as a predictor for the level of amputation in diabetic patients with foot ulcer. Foot Ankle. 1993;14(5):247–53. 14:247-253.

Carter SA. Ankle and toe systolic pressures comparison of value and limitations in arterial occlusive disease. Int Angiol. 1992;11:289–97.

Holstein P. Ischaemic wound complications in above-knee amputations in relation to the skin perfusion pressure. Prosthet Orthot Int. 1980;4:81–6.

Castronuovo Jr JJ, Adera HM, Smiell JM, Price RM. Skin perfusion pressure measurement is valuable in the diagnosis of critical limb ischemia. J Vasc Surg. 1997;26:629–37.

Tsai FW, Tulsyan N, Jones DN, Abdel-Al N, Castronuovo Jr JJ, Carter SA. Skin perfusion pressure of the foot is a good substitute for toe pressure in the assessment of limb ischemia. J Vasc Surg. 2000;32:32–6.

Okamoto T, Oka M, Maesato K, et al. Peripheral arterial occlusive disease is more prevalent in patients with hemodialysis: comparison with the findings of multidetector-row computed tomography. Am J Kid Dis. 2006;48:269–76.

O'Hare A. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol. 2001;12:2838–47.

Leskinen Y, Salenius JP, Lehtimaki T, Huhtala H, Saha H. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis. 2002;40:472–9.

De Vinuesa SG, Ortega M, Martinez P, Golcoechea M, Campdera FG, Luno J. Subclinical peripheral arterial disease in patients with chronic kidney disease: prevalence and related risk factors. Kidney Int Suppl. 2005;67:S44–7.

Han KH, O’Neill WC. Increased peripheral arterial calcification in patients receiving Warfarin. J Am Heart Assoc. 2016;5:1.

Kestenbaum B1, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520–8.

Isakova T, Ix JH, Sprague SM, Raphael KL, Fried L, Gassman JJ, Raj D, Cheung AK, Kusek JW, Flessner MF, Wolf M, Block GAJ. Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. J Am Soc Nephrol. 2015;26:2328–39.

Kuro-o M. Klotho in chronic kidney disease—what’s new? Nephrol Dial Trans. 2009;24:1705–8.

de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS. 25-Hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol. 2009;20:1805–12.

Seiler S, Rogacev KS, Roth HJ, Shafein P, Emrich I, Neuhaus S, Floege J, Fliser D, Heine GH. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Clin J Am Soc Nephrol. 2014;9:1049–58.

Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M. Chronic renal insufficiency cohort (CRIC) study investigators. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014;25:349–60.

Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol. 2006;17(5):1466–71.

Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephron. 2008;19(6):1204–11.

Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, Pandey R. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015;66(6):945–50.

Zang W, Iso H, Murakami Y, Miura K, Nagai M, Sugiyama D, Ueshima H, Okamura T, EPOCH-JAPAN Group. Serum uric acid and mortality from cardiovascular disease: EPOCH-JAPAN study. J Atheroscler Thromb. 2016;23:692–703.

Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med. 1976;295:369–77.

Ross R. The pathogenesis of atherosclerosis—an update. N Engl J Med. 1986;314:488–500.

Drüeke TB. Arterial intima and media calcification: distinct entities with different pathogenesis or all the same? Clin J Am Soc Nehrol. 2008;3:1583–4.

Shuto E, Taketani Y, Tanaka R, Harada N, Issiki M, Sato M, Nashiki K, Amo K, Yamamoto H, Nakaya Y, Takeda E. Dietary phosphorus acutely impairs endothelial function. JASN. 2009;20:1504–12.

Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010;21:1427–35.